Renalytix 配当と自社株買い

配当金基準チェック /06

Renalytix配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-42.4%

バイバック利回り

総株主利回り	-42.4%
将来の配当利回り	n/a
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
配当性向	n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

Renalytix: The Investment Case Is Shot

Jul 25

Renalytix AI GAAP EPS of -$0.20, revenue of $0.81M

Jun 30

Renalytix: High Growth Artificial Intelligence Play, Nearing A Possible Breakout

Apr 05

決済の安定と成長

配当データの取得

安定した配当: RNLX.Yの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: RNLX.Yの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Renalytix 配当利回り対市場

RNLX.Y 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (RNLX.Y)	n/a
市場下位25% (US)	1.4%
市場トップ25% (US)	4.2%
業界平均 (Healthcare Services)	0.9%
アナリスト予想 (RNLX.Y) (最長3年)	n/a

注目すべき配当: RNLX.Yは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: RNLX.Yは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: RNLX.Yの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: RNLX.Yが配当金を報告していないため、配当金の持続可能性を計算できません。

Renalytix 配当と自社株買い

配当金 基準チェック /06

主要情報

最近の配当と自社株買いの更新

Recent updates

Renalytix Plc Provides Revenue Guidance for Years 2025, 2026 and 2027

Renalytix Plc announced delayed 10-Q filing

Renalytix plc Announces Board Changes

Renalytix plc Announces Step Down of Dan Levangie, Non-Executive Director from the Board

Renalytix Plc(OTCPK:RNLX.Y) dropped from NASDAQ Composite Index

Renalytix Plc has completed a Follow-on Equity Offering in the amount of £11.80454 million.

Nasdaq Grants Listing Extension to Renalytix

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

Renalytix Provides Non-Compliance Update

Renalytix Plc Announces Chief Financial Officer Changes

Renalytix Plc Reports Impairment Loss on Property, Equipment and Other Long-Lived Assets for the Third Quarter Ended March 31, 2024

Renalytix Plc to Report Q3, 2024 Results on May 15, 2024

Renalytix plc Announces Executive Changes, Effective from April 30, 2024

Renalytix Plc has filed a Follow-on Equity Offering in the amount of $1 million.

Renalytix Plc has filed a Follow-on Equity Offering in the amount of $4 million.

Renalytix Plc, Annual General Meeting, Apr 22, 2024

Renalytix plc's KidneyIntelX Included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease

Renalytix Plc has completed a Follow-on Equity Offering in the amount of £9.360374 million.

Renalytix Plc has filed a Follow-on Equity Offering in the amount of £7.8 million.

Centers for Medicare & Medicaid Services Publishes Draft Local Coverage Determination for Renalytix Plc's Kidneyintelx and Kidneyintelx.Dkd

Renalytix plc Announces Update on Kidneyintelx.Dkd Local Coverage Determination Consideration

Renalytix Receives Non-Compliance Notice From Nasdaq

Renalytix Receives Non-Compliance Notice From Nasdaq

Renalytix plc Announces Step Down of Chirag Parikh as Independent Non-Executive Director

Renalytix Plc to Report Q1, 2024 Results on Nov 14, 2023

Renalytix Plc, Annual General Meeting, Dec 15, 2023

Renalytix Plc Announces the Stepped Down of Timothy Scannell as Independent Non-Executive Director

Renalytix Plc to Report Second Half, 2023 Results on Sep 28, 2023

Renalytix plc Announces the Appointment of Howard Doran as Chief Business Officer

Renalytix plc Announces Appointments to Its Clinical Advisory Board

Renalytix Plc Announces Late-Breaking KidneyIntelX Evidence Released at American Diabetes Association Scientific Sessions

Renalytix plc Appoints Catherine Coste to Board of Directors, Non-Executive Chair of the Audit Committee and a Member of the Remuneration Committee

Fda Grants De Novo Marketing Authorization for Kidneyintelx.Dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease of Renalytix plc

Renalytix Plc Announces KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences

New major risk - Financial position

Renalytix Plc to Report Q3, 2023 Results on Jun 09, 2023

Renalytix Plc, Annual General Meeting, Jun 08, 2023

Renalytix plc Announces the Launch of PRIME-CKD

Renalytix plc Announces That Primary Care Use of Kidneyintelx in Early Stage Ckd Improved Clinical Care Delivery and Outcomes

Renalytix Plc to Report Q1, 2023 Results on Nov 30, 2022

Renalytix Plc, Annual General Meeting, Dec 19, 2022

Renalytix Plc to Report Q4, 2022 Results on Oct 31, 2022

Renalytix plc Announces Ann Berman, Non-Executive Director and Chair of the Audit and Nomination Committees, Resigns as Director

Renalytix Plc Announces Publication of Clinical Utility Study in The AJMC

Renalytix: The Investment Case Is Shot

Renalytix AI GAAP EPS of -$0.20, revenue of $0.81M

Renalytix Plc to Report Q3, 2022 Results on Jun 30, 2022

Renalytix Plc Announces 1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients

Renalytix Helds Two Data Presentations on Kidneyintelx at American Diabetes Association 82nd Scientific Sessions

Renalytix: High Growth Artificial Intelligence Play, Nearing A Possible Breakout

Renalytix Plc announced that it expects to receive $21.2 million in funding from Heights Capital Ireland, Llc

Renalytix plc Reaches Enrollment Milestone for Building Kidneyintelx as Premier Precision Medicine Platform for Kidney Disease and Diabetes

Renalytix plc Announces the Launch of Its New Provider Access Portal, myIntelX

Renalytix plc Announces the Presentation of New Clinical Data for KidneyIntelX Bioprognostictm Testing At the World Congress of Nephrology Annual Meeting

Renalytix Announces Positive Study Results Published for KidneyIntelX™ in Monitoring Patient Response to New Drug Therapy

Renalytix: Laying The Foundations For Growth

Renalytix: Building Out A Capability To Ramp Revenue

Renalytix plc Announces Scaled-Up Implementation of the KidneyIntelX

Renalytix plc Announces Publication of Results from an External Chronic Kidney Disease Budget Impact Analysis

Renalytix AI EPS beats by $0.06, misses on revenue

決済の安定と成長

配当利回り対市場

株主への利益配当

株主配当金

高配当企業の発掘

配当金基準チェック /06